TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24837862

Group type: EXPERIMENTAL
Intervention: Total body wrapping (covering both body and head with a polyethylene occlusive bag, face uncovered)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment (covering only the body up to the shoulders with a polyethylene occlusive bag)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Total body wrapping
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 100
Study: 22575396

Group type: EXPERIMENTAL
Intervention: Endoscopic placement of an expandable stent
Number of subjects: 22

Group type: COMPARATOR
Intervention: Diverting proximal colostomy
Number of subjects: 22
Study: 20233202

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg b.i.d.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg t.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18477491

Group type: EXPERIMENTAL
Intervention: Conventional regimen (13 cycles with 21 days of treatment + 7 days without hormones)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (four extended cycles with 84 days of continuous administration of EE/DNG, followed by a hormone-free interval of 7 days)
Number of subjects: 59
Study: 15816785

Group type: COMPARATOR
Intervention: mirtazapine 30 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: escitalopram 10 mg and 20 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 12551662

Group type: EXPERIMENTAL
Intervention: Acrylic IOL (MA60BM, Alcon) via temporal corneal incision (Group A)
Number of subjects: 3831

Group type: EXPERIMENTAL
Intervention: Acrylic IOL (MA60BM) via superior sclerocorneal incision (Group B)
Number of subjects: 3831

Group type: EXPERIMENTAL
Intervention: Silicone poly(methyl methacrylate) IOL (SI‐40NB, Allergan) via superior sclerocorneal incision (Group C)
Number of subjects: 3831

Group type: COMPARATOR
Intervention: Comparison of Groups B and C to Group A
Number of subjects: 3831
Study: 10376483

Group type: EXPERIMENTAL
Intervention: BSS:BSSG mixture (active capsules)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 17
Study: 8777303

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg bd + Clarithromycin 250 mg bd + Tinidazole 500 mg bd
Number of subjects: 90

Group type: COMPARATOR
Intervention: Lansoprazole 15 mg bd + Amoxicillin 750 mg bd + Metronidazole 500 mg bd
Number of subjects: 90
Study: 1647185

Group type: EXPERIMENTAL
Intervention: Radiotherapy with 30 mg/m2 cisplatin once a week
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Radiotherapy with 6 mg/m2 cisplatin daily
Number of subjects: 177

Group type: COMPARATOR
Intervention: Radiation alone (55 Gy, split course)
Number of subjects: 177
Study: 6337497

Group type: EXPERIMENTAL
Intervention: levobunolol 0.3%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: levobunolol 0.6%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: levobunolol 1%
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: levobunolol 2%
Number of subjects: 48

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48
Study: 31633158

Group type: EXPERIMENTAL
Intervention: Lopinavir-Ritonavir (LPV/r)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Lopinavir
Number of subjects: 159
Study: 30415751

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Plus™ (NWFP) interactive video games, 14 training sessions, 50 minutes each, twice a week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit Plus™ (NWFP) interactive video games
Number of subjects: 30

Group type: COMPARATOR
Intervention: General advice regarding the importance of physical activity (Control Group)
Number of subjects: 30
Study: 27118812

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) >3 mg/L
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) >10 mg/L
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Higher CRP levels
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Higher HNE levels
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: CRP levels adjusted for severity of acute illness and pre-existing co-morbidity
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: HNE levels adjusted for severity of acute illness and pre-existing co-morbidity
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: HCMV seropositivity at ICU discharge
Number of subjects: 184
Study: 24557088

Group type: EXPERIMENTAL
Intervention: Dutasteride (4 mg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 23251997

Group type: EXPERIMENTAL
Intervention: Continuous intravenous lidocaine infusion of 2 mg/kg/h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 50
Study: 20483149

Group type: EXPERIMENTAL
Intervention: E. coli 83972 bacteriuria
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 20
Study: 18559876

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC; 3 g/m² every 12 hours on days 1, 3, and 5 or 400 mg/m²/d x 5 days)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDAC; 100 mg/m²/d x 5 days)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC)
Number of subjects: 185
Study: 15777307

Group type: EXPERIMENTAL
Intervention: Clonidine (150 microg) as adjuvant for lidocaine (40 ml of lidocaine at 10 mg/ml)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Lidocaine (40 ml of lidocaine at 10 mg/ml) with saline
Number of subjects: 28
Study: 11953281

Group type: EXPERIMENTAL
Intervention: Oxygenated water
Number of subjects: 66

Group type: COMPARATOR
Intervention: Tap water
Number of subjects: 66
Study: 10082242

Group type: EXPERIMENTAL
Intervention: 25 microg of CCK4
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8970867

Group type: EXPERIMENTAL
Intervention: Mitomycin C‐aided trabeculectomy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Trabeculectomy without mitomycin C (Control)
Number of subjects: 52
Study: 2326538

Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: iopamidol
Number of subjects: 50
Study: 6450393

Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation (TES)
Number of subjects: 0
Study: 31996186

Group type: EXPERIMENTAL
Intervention: 200 mg/kg bovine lactoferrin (bLF) in breast/donor human milk or formula milk until 34 weeks corrected gestation or for a minimum of 2 weeks, whichever is longer, or until discharge home or transfer, if earlier
Number of subjects: 500

Group type: COMPARATOR
Intervention: No bovine lactoferrin (bLF) with daily feeds
Number of subjects: 500
Study: 31092224

Group type: EXPERIMENTAL
Intervention: Oral cholera vaccine (OCV)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041
Study: 28893974

Group type: EXPERIMENTAL
Intervention: Intradermal vaccination (V1, n=138)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Intramuscular vaccination (V2, n=144)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Control group (CG, n=138)
Number of subjects: 420
Study: 26053457

Group type: EXPERIMENTAL
Intervention: Patient Safety Indicators (PSIs)
Number of subjects: 444751

Group type: EXPERIMENTAL
Intervention: Hospital-Acquired Conditions (HACs)
Number of subjects: 444751

Group type: COMPARATOR
Intervention: High-volume hospitals
Number of subjects: 444751

Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 444751
Study: 23537311

Group type: EXPERIMENTAL
Intervention: URS combined with RIRS
Number of subjects: 94

Group type: COMPARATOR
Intervention: URS alone
Number of subjects: 94
Study: 21436390

Group type: EXPERIMENTAL
Intervention: Higher intensity RT
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lower intensity RT
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR)
Number of subjects: 18
Study: 19095869

Group type: EXPERIMENTAL
Intervention: Ilioinguinal‐Iliohypogastric (IG‐IH) and lower intercostal nerve block with bupivacaine 0.5%
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 42
Study: 18076528

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1032
Study: 15184252

Group type: EXPERIMENTAL
Intervention: Interventions to achieve physician consensus, practice changes, and patient activation
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: HMO membership or insurance coverage for six screening procedures
Number of subjects: 2520

Group type: EXPERIMENTAL
Intervention: Clinic staff recommendations for six screening procedures
Number of subjects: 2520
Study: 11434597

Group type: COMPARATOR
Intervention: High-dose interferon alpha (IFN-α) alone (5 MU/TIW followed by 10 MU/TIW for 3 months)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha (IFN-α) with ribavirin (approximately 14 mg/kg/day for 3 months)
Number of subjects: 304

Group type: COMPARATOR
Intervention: High-dose interferon alpha (IFN-α) alone (group A)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: High-dose interferon alpha (IFN-α) with ribavirin (group B)
Number of subjects: 304
Study: 11732520

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg) given 3 hours before induction of anaesthesia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Erythromycin (200 mg) given 1 hour before induction of anaesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (nothing with 10 ml water)
Number of subjects: 60
Study: 9197945

Group type: EXPERIMENTAL
Intervention: RP 60180 (1.0 mg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pentazocine (50 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 1550907

Group type: COMPARATOR
Intervention: 100 mg t.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: 350 mg b.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: 350 mg t.i.d.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3926229

Group type: EXPERIMENTAL
Intervention: Treatment with iodine-131 or carbimazole in hyperthyroid patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Thyroxine replacement therapy in hypothyroid patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Standard doses of thyroxine replacement therapy in hypothyroid patients
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Standard chemical tests of liver function
Number of subjects: 22
Study: 29262693

Group type: EXPERIMENTAL
Intervention: Complex version of the ACT matrix app
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Simple version of the ACT matrix app
Number of subjects: 98

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 98
Study: 29741615

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 1376

Group type: COMPARATOR
Intervention: SAVR
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Dilated RV
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: More than mild tricuspid regurgitation (TR)
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Worsening RV function
Number of subjects: 1376

Group type: EXPERIMENTAL
Intervention: Development of moderate or severe RV dysfunction from baseline normal RV function
Number of subjects: 1376
Study: 27667464

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Hydroxychloroquine (HCQ)
Number of subjects: 66
Study: 24797938

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3×5 min blood pressure cuff inflation/5 min deflation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (cuff deflated)
Number of subjects: 20
Study: 22569857

Group type: EXPERIMENTAL
Intervention: Nonpenetrating very deep sclerectomy (NPVDS) with hyaluronic acid implant
Number of subjects: 68

Group type: COMPARATOR
Intervention: Trabeculectomy (TB)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Nonpenetrating very deep sclerectomy (NPVDS)
Number of subjects: 68
Study: 20360622

Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (267 mg/daily)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control subjects (normal lipid profile)
Number of subjects: 125
Study: 18790510

Group type: EXPERIMENTAL
Intervention: Glatiramer acetate
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 15620502

Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 33

Group type: COMPARATOR
Intervention: Non-absorbable sutures
Number of subjects: 33
Study: 11843506

Group type: EXPERIMENTAL
Intervention: Homograft (group H)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Medtronic Freestyle bioprosthesis (group F)
Number of subjects: 137
Study: 10102947

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy with amoxycillin 1000 mg b.d., clarithromycin 500 mg b.d., and lansoprazole 30 mg b.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1-day quadruple therapy with amoxycillin 2000 mg q.d.s., clarithromycin 500 mg q.d.s., lansoprazole 30 mg t.d.s., and bismuth subcitrate 240 mg q.d.s.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 7-day triple therapy (same as above) for re-treatment of patients who failed 1-day treatment.
Number of subjects: 30
Study: 8537068

Group type: EXPERIMENTAL
Intervention: Right and left anterior atrial branches and right and left posterior atrial branches
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Type of coronary arteries ramifications
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Anastomoses between branches of the right and left coronary arteries
Number of subjects: 130
Study: 2299563

Group type: EXPERIMENTAL
Intervention: Bio-Pen biometric ruler
Number of subjects: 207

Group type: COMPARATOR
Intervention: Kretz 7200 MA A-scan unit
Number of subjects: 207
Study: 31793529

Group type: EXPERIMENTAL
Intervention: Frinozol nasal spray (Phenylephrine + Cetyrizine) 2 sprays per each nostril three times a day for 7 days
Number of subjects: 134

Group type: COMPARATOR
Intervention: Vibrocil 2 sprays per each nostril three times a day for 7 days
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Frinozol nasal spray (Phenylephrine + Cetyrizine)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Vibrocil
Number of subjects: 134
Study: 28202383

Group type: EXPERIMENTAL
Intervention: Tailored program of physical therapy focused on progressive training in strength, balance, and gait for a period of 3 months, along with screening and follow‐up for vision, polypharmacy, and environmental hazards
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Tailored program of physical therapy
Number of subjects: 354

Group type: COMPARATOR
Intervention: Usual care prescribed by a physician and educational materials on falls prevention
Number of subjects: 354
Study: 25884192

Group type: EXPERIMENTAL
Intervention: Probiotic strain Lactobacillus paracasei SD1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no probiotics)
Number of subjects: 60
Study: 24020899

Group type: EXPERIMENTAL
Intervention: pioglitazone 45 mg daily
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34
Study: 21949991

Group type: EXPERIMENTAL
Intervention: 70 mg ginaton by vein, once a day for 14 days (Group A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 10 microg Alprostadil injection by vein, once a day for 14 days (Group B)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: 10 microg Alprostadil injection and ginaton by vein, once a day for 14 days (Group C)
Number of subjects: 91
Study: 19416095

Group type: EXPERIMENTAL
Intervention: Pilocarpine 1% (60 microg kg(‐1) body-weight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cevimeline (30 mg)
Number of subjects: 40
Study: 17876389

Group type: EXPERIMENTAL
Intervention: Temporal pole signal abnormality (TPA) in patients with HS
Number of subjects: 120
Study: 14986190

Group type: EXPERIMENTAL
Intervention: Sprint training (S)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 17
Study: 11564829

Group type: EXPERIMENTAL
Intervention: IL-10 administered subcutaneously for 28 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9563670

Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate Aqueous Nasal Spray (FPANS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 7970533

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) at one sitting
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) at two sittings
Number of subjects: 29
Study: 3044575

Group type: EXPERIMENTAL
Intervention: Segmentectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mastectomy
Number of subjects: 0
Study: 31747481

Group type: EXPERIMENTAL
Intervention: High Definition Laryngoscopy (HDL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Fiberoptic Laryngoscopy (FOL)
Number of subjects: 36
Study: 28320220

Group type: EXPERIMENTAL
Intervention: Yiqiqubai granule
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: 308-nm excimer laser
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Combined treatments (Yiqiqubai granule + 308-nm excimer laser)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 233
Study: 24930619

Group type: EXPERIMENTAL
Intervention: Radioembolization with yttrium-90 resin microspheres followed by sorafenib (200 mg twice daily escalating to 400 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sorafenib only (matching dose schedule to the intervention arm)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Radioembolization plus sorafenib
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sorafenib only
Number of subjects: 40
Study: 23444220

Group type: EXPERIMENTAL
Intervention: Sorafenib plus gemcitabine/capecitabine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine/capecitabine
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 21238993

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 17635103

Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise at 60% of VO2peak for 30-120 min expending 1.28-5.76 MJ
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rest (control group)
Number of subjects: 30
Study: 16877419

Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg three times a day for two periods of 5 days)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12917202

Group type: EXPERIMENTAL
Intervention: Exercise training (n = 25)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (n = 28)
Number of subjects: 53
Study: 10718775

Group type: COMPARATOR
Intervention: Intravenous morphine (5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Subcutaneous bolus morphine (5 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Subcutaneous infusion morphine (5 mg)
Number of subjects: 6
Study: 8938809

Group type: EXPERIMENTAL
Intervention: Vicryl suture
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 6
Study: 1525789

Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg TID
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg TID
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ranitidine 150 mg BID
Number of subjects: 60
Study: 3885848

Group type: EXPERIMENTAL
Intervention: 0.1 ml of intradermal BCG vaccine
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: 0.1 ml of intradermal BCG vaccine (second inoculation)
Number of subjects: 155
Study: 28882076

Group type: EXPERIMENTAL
Intervention: Bicycling intervention over 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28851799

Group type: EXPERIMENTAL
Intervention: Loop electrosurgical excision procedure (LEEP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cold knife cone biopsy (CKC)
Number of subjects: 0
Study: 26677350

Group type: EXPERIMENTAL
Intervention: Whey protein (30 g)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Isocaloric carbohydrates (maltodextrin)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Protein + carbohydrates
Number of subjects: 68
Study: 23374002

Group type: EXPERIMENTAL
Intervention: 1% nystatin
Number of subjects: 158

Group type: COMPARATOR
Intervention: 2.5% sodium bicarbonate
Number of subjects: 158

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 158
Study: 21601481

Group type: EXPERIMENTAL
Intervention: Target Hb value in normal range (130‐149 g/l), group 2, n=46
Number of subjects: 89

Group type: COMPARATOR
Intervention: Target Hb value in subnormal range (110‐129 g/l), group 1, n=43
Number of subjects: 89
Study: 18930977

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic screening (PGS) using FISH for chromosomes X, Y, 13, 16, 18, 21, 22
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no PGS)
Number of subjects: 120
Study: 16497643

Group type: EXPERIMENTAL
Intervention: Surgical treatment (orchidopexy) at 9 months
Number of subjects: 149

Group type: COMPARATOR
Intervention: Non-treatment (control group) at 3 years
Number of subjects: 149
Study: 15240203

Group type: EXPERIMENTAL
Intervention: Computer‐assisted retraining of memory and attention (study arm)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Visuo‐constructional and visuo‐motor coordination (control arm)
Number of subjects: 82
Study: 11565517

Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg daily)
Number of subjects: 1715

Group type: COMPARATOR
Intervention: Amlodipine (10 mg daily)
Number of subjects: 1715

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1715
Study: 9274477

Group type: EXPERIMENTAL
Intervention: Total fundic wrap (Nissen-Rossetti)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 180 degrees semifundoplication (Toupet)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nissen-Rossetti
Number of subjects: 33
Study: 8297658

Group type: EXPERIMENTAL
Intervention: 4‐HPR 200 mg/day
Number of subjects: 149

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 149